DB:IF0

Stock Analysis Report

Executive Summary

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.

Risk Analysis

Earnings are forecast to decline by an average of -11.5% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Does not have a meaningful market cap (€88M)



Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has InflaRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IF0's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.1%

IF0

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

-89.2%

IF0

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: IF0 underperformed the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: IF0 underperformed the German Market which returned 15% over the past year.


Shareholder returns

IF0IndustryMarket
7 Day9.1%1.0%2.0%
30 Day-5.5%-1.2%1.0%
90 Day50.0%7.4%3.8%
1 Year-89.2%-89.2%7.1%6.8%18.6%15.1%
3 Yearn/a48.3%46.6%16.8%6.6%
5 Yearn/a11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is InflaRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is InflaRx undervalued compared to its fair value and its price relative to the market?

0.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IF0's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IF0's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IF0 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IF0 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IF0's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IF0 is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is InflaRx forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-11.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IF0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IF0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IF0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IF0's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if IF0's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IF0 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has InflaRx performed over the past 5 years?

-45.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IF0 is currently unprofitable.

Growing Profit Margin: IF0 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IF0 is unprofitable, and losses have increased over the past 5 years at a rate of -45.8% per year.

Accelerating Growth: Unable to compare IF0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IF0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: IF0 has a negative Return on Equity (-40.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is InflaRx's financial position?


Financial Position Analysis

Short Term Liabilities: IF0's short term assets (€138.7M) exceed its short term liabilities (€17.8M).

Long Term Liabilities: IF0's short term assets (€138.7M) exceed its long term liabilities (€615.4K).


Debt to Equity History and Analysis

Debt Level: IF0 is debt free.

Reducing Debt: IF0 had no debt 5 years ago.


Balance Sheet

Inventory Level: IF0 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IF0's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IF0 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IF0 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -55.3% each year.


Next Steps

Dividend

What is InflaRx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IF0's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IF0's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IF0's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IF0's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IF0's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average management tenure


CEO

Niels Riedemann (47yo)

13.1yrs

Tenure

0

Dr. Niels C. Riedemann, M.D. is a Co-Founder of InflaRx GmbH and has been its Chief Executive Officer and Executive Director since 2007. Dr. Riedemann spent several years in basic science at the University ...


Leadership Team

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder13.1yrsno data3.82% 3.1m
Renfeng Guo
Co-Founder0yrsno data4% 3.3m
Arnd Christ
Chief Financial Officer4.8yrsno data0.024% 20.0k
Jason Marks
Chief Legal Officer1.1yrsno datano data
Jordan Silverstein
Head of Corporate Development & Strategy0yrsno datano data
Maria Habel
Head of Preclinical Research & Development7.1yrsno datano data
Katrin Reiher
Head of Quality Management7.1yrsno datano data
Jordan Zwick
Global Head of Business Development & Corporate Strategy0yrsno datano data

7.1yrs

Average Tenure

45yo

Average Age

Experienced Management: IF0's management team is seasoned and experienced (7.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder13.1yrsno data3.82% 3.1m
Renfeng Guo
Co-Founder0yrsno data4% 3.3m
Katrin Uschmann
Non-Executive Director13.1yrsno datano data
Nicolas Fulpius
Chairman of the Board13.1yrsno data1.58% 1.3m
Jens Holstein
Non-Executive Director1.4yrsno datano data
K. Reinhart
Member of Scientific Advisory Board0yrsno datano data
P. Ward
Member of Scientific Advisory Board0yrsno datano data
Richard Brudnick
Non-Executive Director0.8yrsno datano data
Lina Ma
Non-Executive Director3.4yrsno datano data
Mark Kubler
Non-Executive Director5.1yrsno data2.82% 2.3m

4.3yrs

Average Tenure

48yo

Average Age

Experienced Board: IF0's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

InflaRx N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InflaRx N.V.
  • Ticker: IF0
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$88.497m
  • Listing Market Cap: US$81.683m
  • Shares outstanding: 26.11m
  • Website: https://www.inflarx.de

Number of Employees


Location

  • InflaRx N.V.
  • Winzerlaer Str. 2
  • Jena
  • Thuringia
  • 7745
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IFRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
IF0DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017
IFRX NBMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2017

Biography

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase II clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 22:37
End of Day Share Price2020/02/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.